Previous close | 8.50 |
Open | 8.41 |
Bid | 8.24 x 200 |
Ask | 9.21 x 200 |
Day's range | 8.41 - 8.41 |
52-week range | 4.97 - 63.38 |
Volume | |
Avg. volume | 73,156 |
Market cap | 41.245M |
Beta (5Y monthly) | 0.53 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
GSK's depemokimab has the potential to become the first ultra-long-acting biologic for severe asthma with a six-month dosing schedule
Atara Biotherapeutics ( NASDAQ:ATRA ) First Quarter 2024 Results Key Financial Results Revenue: US$27.4m (up by...